Articles From: Pfizer ekes out gains on a down market day to PFSweb Launches New eCommerce Solution for ASICS Corporation


2015/1/27
By Russ Britt, MarketWatch Drug giant overcomes patent woes and beats forecasts LOS ANGELES (MarketWatch) -- While the rest of the market was sinking, shares of drug giant Pfizer Inc. managed to eke out gains early Tuesday after Wall Street decided the company's fourth-quarter results were more critical than its 2015 projections.
Sign-up for Pfizer ekes out gains on a down market day investment picks
2014/12/8
Pfizer Inc. (NYSE:PFE) announced today two strategic decisions to expand the company’s rare disease research and development activities through the establishment of a gene therapy platform to investigate potential treatments for patients.
Sign-up for Pfizer Expands Rare Disease Research with Establishment of Gene Therapy Platform investment picks
2015/2/6
Pfizer Inc. (PFE) filed a Form 8K - Entry Into a Definitive Agreement - with the U.S Securities and Exchange Commission on February 06, 2015.
Sign-up for Pfizer Files 8K - Entry Into Definitive Agreement investment picks
2015/2/10
Pfizer Inc. (PFE) filed a Form 8K - Other Events - with the U.S Securities and Exchange Commission on February 10, 2015.
Sign-up for Pfizer Files 8K - Other Events investment picks
2015/2/3
Pfizer Inc. (PFE) said late Tuesday it received accelerated Food and Drug Administration approval for its breast cancer drug Inbrance.
Sign-up for Pfizer gets FDA approval for breast cancer drug Inbrance investment picks
2015/1/27
By Michael Calia Pfizer Inc. issued downbeat guidance for the new year, citing the stronger U.S. dollar and recent drug-patent losses, and reported a decline in sales in the most recent period.
Sign-up for Pfizer Hit by Stronger Dollar, Patent Losses investment picks
2015/1/27
By Jonathan D.
Sign-up for Pfizer Hit by Stronger Dollar, Patent Losses -- 2nd Update investment picks
2015/1/27
By Michael Calia Pfizer Inc. issued downbeat guidance for the new year, citing the stronger U.S. dollar and recent drug-patent losses, and reported a decline in sales in the most recent period.
Sign-up for Pfizer Hit by Stronger Dollar, Patent Losses -- Update investment picks
2015/1/27
By Jonathan D.
Sign-up for Pfizer Hit by Stronger Dollar, Patent Losses, Lawsuit Settlement -- 3rd Update investment picks
2014/12/17
Pfizer Inc. (NYSE:PFE) announced today enrollment of the first patient in a multicenter Phase II clinical trial of the investigational compound PF-06252616 in boys with Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness.
Sign-up for Pfizer Initiates Phase 2 Study of PF-06252616 in Duchenne Muscular Dystrophy investment picks
2015/2/5
Pfizer will hold an analyst and investor call to discuss its proposed acquisition of Hospira at 9:00 AM EST (2:00 PM GMT) today, February 5, 2015.
Sign-up for Pfizer Invites Investors, Analysts And Media To Join Conference Calls Discussing Pfizer’s Proposed Acquisition of Hospira investment picks
2015/2/24
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Ian Read, Chairman and CEO, Mikael Dolsten, President, Worldwide Research and Development, and Albert Bourla, Group President, Vaccines, Oncology and Consumer Healthcare Business, at the Cowen and Company 35 th Annual Healthcare Conference on Tuesday, March 3, 2015 at 10:00 a.m. Eastern Standard Time.
Sign-up for Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference investment picks
2015/2/9
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Ian Read, Chairman and CEO, at the BIO CEO and Investor Conference on Tuesday, February 10, 2015 at 3:30 p.m. Eastern Standard Time.
Sign-up for Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Investor Conference investment picks
2014/12/16
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 27, 2015.
Sign-up for Pfizer Invites Public to View and Listen to Webcast of January 27 Conference Call with Analysts investment picks
2015/1/6
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the 33 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 at 2:30 p.m. Pacific Standard Time.
Sign-up for Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference investment picks
2015/2/4
Pfizer Inc. today announced a grant to the Union for International Cancer Control (UICC) for a first-of-its-kind initiative to address the unique challenges facing metastatic breast cancer (MBC) patients.
Sign-up for Pfizer Marks World Cancer Day with Grant to Union for International Cancer Control to Address the Needs of Metastatic Breast Cancer Patients investment picks
2015/1/8
The U.S. Food and Drug Administration (FDA) has informed Pfizer Inc. that at this time there is no plan for an Oncologic Drugs Advisory Committee meeting for IBRANCE ® (palbociclib). Pfizer continues to have an open and productive dialogue with the FDA as the application for IBRANCE advances.
Sign-up for Pfizer Provides Update on IBRANCE® (palbociclib) investment picks
2015/2/3
Pfizer Inc. today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of IBRANCE ® (palbociclib), in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer as initial endocrine-based therapy for their metastatic disease.
Sign-up for Pfizer Receives U.S. FDA Accelerated Approval of IBRANCE® (palbociclib) investment picks
2015/1/27
Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2014.
Sign-up for PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2014 RESULTS; PROVIDES 2015 FINANCIAL GUIDANCE investment picks
2014/12/18
Pfizer Inc. (NYSE:PFE) announced today top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia (pain after shingles or PHN). The results show that pregabalin CR resulted in a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR) in pain reduction.
Sign-up for Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia investment picks
2015/2/5
Pfizer Inc. (NYSE:PFE) and Hospira, Inc. (NYSE:HSP) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Hospira, the world’s leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, for $90 a share in cash for a total enterprise value of approximately $17 billion.
Sign-up for Pfizer To Acquire Hospira investment picks
2015/2/5
By Lauren Pollock and George Stahl Pfizer Inc. agreed to buy Hospira Inc., a maker of injectable drugs and infusion technologies, for about $16 billion.
Sign-up for Pfizer to buy Hospira for $16 billion investment picks
2015/2/5
By Jonathan D.
Sign-up for Pfizer to Buy Hospira for $16 Billion -- 5th Update investment picks
2015/2/5
By Jonathan D.
Sign-up for Pfizer to Buy Hospira for $16 Billion -- 6th Update investment picks
2015/2/5
Pfizer (PFE) announced on Thursday an agreement to buy Hospira (HSP) in a cash deal valuing the provider of injectable drugs at $17 billion.
Sign-up for Pfizer to buy Hospira in $17 billion cash deal investment picks
2014/12/15
By Angela Chen OPKO will get upfront payment of $295 million and is eligible for up to $275 million more Pfizer Inc. and OPKO Health Inc. have partnered to develop and commercialize an OPKO treatment for growth-hormone deficiency that could replace daily injections with weekly ones.
Sign-up for Pfizer, OPKO Health partner on growth-hormone treatment investment picks
2015/1/27
Shares of Pfizer (PFE) slumped 1.7% in premarket trade Tuesday, after the drug giant provided a downbeat 2015 profit and sales outlook, citing product losses and the negative impact of currency moves.
Sign-up for Pfizer's stock falls after downbeat profit, sales outlook investment picks
2015/2/9
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1173921&ProfileId=051205&sourceType=1 ALLEN, TX --
Sign-up for PFSweb Appoints Travis Hess as Executive Vice President of Sales investment picks
2015/1/6
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1167748&ProfileId=051205&sourceType=1 ALLEN, TX --
Sign-up for PFSweb Expands India Operations and Reports Successful Holiday Season investment picks
2015/2/24
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1177016&ProfileId=051205&sourceType=1 ALLEN, TX --
Sign-up for PFSweb Launches New eCommerce Solution for ASICS Corporation investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Pfizer ekes out gains on a down market day to PFSweb Launches New eCommerce Solution for ASICS Corporation
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent